跳至主要内容
临床试验/NCT03167294
NCT03167294已完成不适用

PROCEPT AQUABEAM Study for the Treatment of Benign Prostatic Hyperplasia (ABS)

PROCEPT BioRobotics2 个研究点 分布在 1 个国家目标入组 47 人开始时间: 2014年12月14日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
47
试验地点
2
主要终点
Primary Device Performance Endpoint

研究概览

简要总结

Single-arm prospective, interventional clinical trial. Results will be compared to a historical control in the treatment of benign prostatic hyperplasia

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 80 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • 50 - 80 years
  • Moderate to severe BPH
  • Subjects who have failed standard medical therapy

排除标准

  • Size and width of prostate
  • Medical condition or co-morbidities where BPH intervention would be contraindicated

研究组 & 干预措施

Single Arm

Other

AquaBeam System for resection and removal of prostatic tissue in males suffering from BPH

干预措施: AquaBeam System (Device)

结局指标

主要结局

Primary Device Performance Endpoint

时间窗: 6 months

The primary device performance endpoint is completion of the intended surgical procedure.

Primary Safety Endpoint of the study is the perioperative complication rate.

时间窗: 6 months

The primary safety endpoint of the study is the perioperative complication rate

次要结局

未报告次要终点

研究者

发起方
PROCEPT BioRobotics
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验